OIG subpoenas United Therapeutics paperwork

Share this article:

The Office of the Inspector General (OIG) of the Department of Health and Human Services is taking a gander at United Therapeutics and its marketing practices. The drugmaker announced Monday that the government agency subpoenaed  “documents regarding...the company's marketing practices relating” to its drugs Remodulin, Tyvaso and Adcirca. All are used to treat pulmonary arterial hypertension (PAH).

The "About Us" section of the OIG's website notes that the HHS Office of the Inspector General is the federal government's largest Office of Inspector General department, and is responsible for sussing out waste, fraud and abuse in HHS programs, which include Medicare and Medicaid, among others.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.